Heron Therapeutics, Inc.
HRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818033
No open-market purchases or sales by Heron Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $68.4M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 163
- 13F valueReported value at the end of Q2 2026
- $57.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $154.9M
- +7.4% year over year
- Net income, FY2025
- -$20.2M
- No comparable prior period
- Free cash flow, FY2025
- -$27.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $35.3M
- −7.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $20.2M (13.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 34.0M
- Shares sold short
- Change
- −2.74M
- −7.5% vs. previous
- Days to cover
- 19.54
- At average daily volume
Superinvestors holding HRTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding HRTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Heron Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchaseCommon Stock, par value $0.01 per share ("Common Stock") | +2.39M | $1.50 | +$3.58M | +8.9%29.1M after | |
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchaseConvertible Senior Unsecured Promissory Notes ("Notes") | – | – | – | – | DerivativePrice outlier |
| Aug 12, 2025 (view filing)6:00 PM ET | Aug 8 | 4 days | Rubric Capital Management LP and 1 other10% Owner | PPurchase | +946.1K | $1.50 | +$1.42M | –94.6K after | Derivative |
| Aug 12, 2025 (view filing) | Aug 8 | 4 days | Morgan AdamDirector | PPurchase | +1.77M | $1.50 | +$2.65M | +25.3%8.75M after | |
| Aug 12, 2025 (view filing) | Aug 8 | 4 days | Morgan AdamDirector | PPurchase | +700.1K | $1.50 | +$1.05M | –70.0K after | Derivative |
| Nov 21, 2023 (view filing) | Nov 17 | 4 days | Forbes William PEVP, Chief Development Officer | PPurchase | +25.0K | $1.09 | +$27.3K | +46.3%79.0K after | |
| Nov 20, 2023 (view filing) | Nov 16 | 4 days | Forbes William PEVP, Chief Development Officer | PPurchase | +50.0K | $0.94 | +$47.0K | +1,250.0%54.0K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Collard Craig AChief Executive Officer | PPurchase | +150.0K | $0.92 | +$138.0K | +411.0%186.5K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Duarte IraEVP, Chief Financial Officer | PPurchase | +85.0K | $0.89 | +$75.7K | New position85.0K after | |
| Jul 25, 2023 (view filing) | Jul 21 | 4 days | Morgan AdamDirector | PPurchaseCommon Stock, par value $0.01 per share | +2.49M | $1.37 | +$3.41M | +55.3%6.99M after |
Top 10 13F holders, Q2 2026
See all 163 holdersThe largest institutional positions in Heron Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 30,046,828 | $12.8M | 0.12% | 00.0% | Unchanged |
| Clearline Capital LP | 11,383,961 | $4.86M | 0.31% | −851,278−7.0% | Reduced |
| BlackRock, Inc. | 10,550,750 | $4.50M | 0.00% | +444,328+4.4% | Added |
| Velan Capital Investment Management LP | 8,753,290 | $3.74M | 2.29% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,782,741 | $3.32M | 0.00% | −27,588−0.4% | Reduced |
| Tejara Capital Ltd | 6,510,795 | $2.78M | 1.14% | +174,040+2.7% | Added |
| Tang Capital Management LLC | 6,250,000 | $2.67M | 0.12% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 4,270,980 | $1.82M | 0.00% | +260,893+6.5% | Added |
| Millennium Management LLC | 4,070,101 | $1.74M | 0.00% | −3,560,426−46.7% | Reduced |
| JW Asset Management, LLC | 3,751,073 | $1.60M | 0.50% | 00.0% | Unchanged |
Holders of 5% or more of HRTX
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Heron Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 13D/A | 15.90%30.0M shares | −1.60 ppfrom 17.50% | Feb 6, 20236 filings | Oct 17, 2025 | SEC |
| Clearline Capital LP | 13G/A | 6.70%12.2M shares | +1.40 ppfrom 5.30% | Nov 26, 20252 filings | Feb 17, 2026 | SEC |
Politician trades
All politician trades in HRTX1 member of Congress reported 1 trade in Heron Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Apr 5, 2021 |  Ashley Hinson House · IA | Sell | $1K-$15K |
House · IA · Apr 5, 2021
Sell$1K-$15K